<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04304040</url>
  </required_header>
  <id_info>
    <org_study_id>MIL62-CT03</org_study_id>
    <nct_id>NCT04304040</nct_id>
  </id_info>
  <brief_title>A Study of MIL62 Combined With Orelabrutinib for the Treatment of R/R CD20+B Cell Lymphoma</brief_title>
  <official_title>A Phase I/IIa Study on Dose-escalation and Extension of Recombinant Humanized Type II CD20 Monoclonal Antibody MIL62 Injection Combined With BTK Inhibitor Orelabrutinib in the Treatment of Recurrent/Refractory CD20+B-cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing InnoCare Pharma Tech Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing InnoCare Pharma Tech Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dose escalation and expansion phase I/IIa clinical study of recombinant humanized type II&#xD;
      CD20 monoclonal antibody MIL62 injection combined with a novel selective Bruton Tyrosine&#xD;
      Kinase(BTK) inhibitor Orelabrutinib in the treatment of recurrent/refractory CD20+B cell&#xD;
      lymphoma&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 28, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2025</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose limiting toxicity (DLT)(Dose escalation phase)</measure>
    <time_frame>At the end of Cycle 1 (each cycle is 28 days)</time_frame>
    <description>Safety observation indicator</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD) (Dose escalation phase)</measure>
    <time_frame>At the end of Cycle 1 (each cycle is 28 days)</time_frame>
    <description>Safety observation indicator</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended dose for phase 2 trials of two-drug combinations (RP2D) (Dose escalation phase)</measure>
    <time_frame>At the end of Cycle 1 (each cycle is 28 days)</time_frame>
    <description>Safety observation indicator</description>
  </primary_outcome>
  <primary_outcome>
    <measure>objective remission rate(ORR) (Dose expansion phase)</measure>
    <time_frame>At the end of Cycle 30 (each cycle is 28 days)</time_frame>
    <description>Efficacy observation indicator</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>objective remission rate(ORR)</measure>
    <time_frame>At the end of Cycle 30 (each cycle is 28 days)</time_frame>
    <description>Efficacy observation indicator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration vs time curve(AUC)</measure>
    <time_frame>At the end of Cycle 6 (each cycle is 28 days)</time_frame>
    <description>pharmacokinetic parameter of MIL62 combined with Orelabrutinib in the treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent half-life for designated elimination phases (t½)</measure>
    <time_frame>At the end of Cycle 6 (each cycle is 28 days)</time_frame>
    <description>pharmacokinetic parameter of MIL62 combined with Orelabrutinib in the treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The peak plasma concentration (Cmax)</measure>
    <time_frame>At the end of Cycle 6 (each cycle is 28 days)</time_frame>
    <description>pharmacokinetic parameter of MIL62 combined with Orelabrutinib in the treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of remission(DOR)</measure>
    <time_frame>3 years after first treatment</time_frame>
    <description>Efficacy observation indicator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival(PFS) in the treatment of R/R CD20+B cell lymphoma</measure>
    <time_frame>3 years after first treatment</time_frame>
    <description>Preliminary evaluation of MIL62 combined with Orelabrutinib in the treatment of relapsed/refractory CD20+B cell lymphoma with 3-year progression-free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival(OS) in the treatment of R/R CD20+B cell lymphoma</measure>
    <time_frame>3 years after first treatment</time_frame>
    <description>Preliminary evaluation of MIL62 combined with Orelabrutinib in the treatment of recurrent/refractory CD20+B cell lymphoma with 3-year overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of remission(DOR) in the treatment of R/R NHL</measure>
    <time_frame>3 years after first treatment</time_frame>
    <description>Preliminary evaluation of remission duration of MIL62 combined with Orelabrutinib in the treatment of Recurrent/refractory Non Hodgkin Lymphoma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival(PFS) in the treatment of R/R NHL</measure>
    <time_frame>3 years after first treatment</time_frame>
    <description>Preliminary evaluation of MIL62 combined with Orelabrutinib in the treatment of Recurrent/refractory Non Hodgkin Lymphoma with 3-year progression-free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival(OS) in the treatment of R/R NHL</measure>
    <time_frame>3 years after first treatment</time_frame>
    <description>Preliminary evaluation of MIL62 combined with Orelabrutinib in the treatment of Recurrent/refractory Non Hodgkin Lymphoma with 3-year overall survival</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>B-cell Lymphoma Recurrent</condition>
  <condition>B-cell Lymphoma Refractory</condition>
  <arm_group>
    <arm_group_label>Single Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Orelabrutinib</intervention_name>
    <description>BTK inhibitor Orelabrutinib low dose or high dose; Part A:28days/cycle, Cycle1:35days; Part B:21 days/cycle, Cycle1:28days.</description>
    <arm_group_label>Single Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Recombinant humanized monoclonal antibody MIL62 injection</intervention_name>
    <description>Recombinant humanized monoclonal antibody MIL62 injection, 800mg or1000mg each time, Part A:28days/cycle, Cycle1:35days; Part B:21 days/cycle, Cycle1:28days.</description>
    <arm_group_label>Single Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥18 years, gender not limited&#xD;
&#xD;
          2. Dose escalation phase: Histologically confirmed CD20 positive B-cell non-Hodgkin's&#xD;
             lymphoma; Expansion stage: R/R NHL Or histologically diagnosed CD20 positive chronic&#xD;
             lymphocytic leukemia/small lymphocytic lymphoma;&#xD;
&#xD;
          3. Dose escalation phase ：Patients who have received at least one treatment regimen&#xD;
             Expansion stage：Patients who have received at least one to four treatment regimens&#xD;
             with at least one regimen containing rituximab;&#xD;
&#xD;
          4. Eastern cancer collaboration group(ECOG) physical status score: 0-2&#xD;
&#xD;
          5. Laboratory tests performed within 7 days prior to the first acceptance of the study&#xD;
             drug met the protocol criteria.&#xD;
&#xD;
          6. Expected survival ≥6 months&#xD;
&#xD;
          7. Sign a written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Expansion stage: DLBCL transformed from follicular lymphoma, DLBCL with follicular&#xD;
             lymphoma, and lymphomas with primary or central nervous system involvement.&#xD;
&#xD;
          2. Received any of the anti-tumor treatments(note in the protocol) before the first study&#xD;
             drug.&#xD;
&#xD;
          3. Previous use of any anticancer vaccine.&#xD;
&#xD;
          4. Patients who had received hematopoietic stem cell transplantation within 3 months&#xD;
             before the first administration&#xD;
&#xD;
          5. Patients scheduled for major surgery within 28 days prior to initial administration or&#xD;
             during the expected study period.&#xD;
&#xD;
          6. Patients who Is participating in other clinical trials or first administration less&#xD;
             than 28 days after the end of the previous clinical trial.&#xD;
&#xD;
          7. Receiving prednisone treatment or other corticosteroid treatment with the same dose as&#xD;
             prednisone ;Patients who require warfarin or an equivalent vitamin K antagonist;&#xD;
&#xD;
          8. During the study period, drugs with moderate or severe inhibition or strong induction&#xD;
             of cytochrome CYP3A4 were taken together;&#xD;
&#xD;
          9. Subject has a history of any of the diseases note in the protocol;&#xD;
&#xD;
         10. Patients with infections;&#xD;
&#xD;
         11. Impact testing scheme compliance or other serious results explain the poor control of&#xD;
             the merger of the disease(note in the protocol);&#xD;
&#xD;
         12. Toxicity of any previous anticancer treatment has not recovered to ≤1, except for hair&#xD;
             loss;&#xD;
&#xD;
         13. A history of severe allergic reactions to humanized monoclonal antibodies or known&#xD;
             allergies to any component of Orelabrutinib or MIL62;&#xD;
&#xD;
         14. Inability to swallow research drugs, or the presence of conditions that significantly&#xD;
             affect gastrointestinal function;&#xD;
&#xD;
         15. Hepatitis b surface antigen (HBsAg) and/or hepatitis b core antibody (HBcAb) are&#xD;
             positive ; Hepatitis c virus (HCV) antibody positive and HCV RNA positive patients;&#xD;
             Human immunodeficiency virus (HIV) serum response was positive;&#xD;
&#xD;
         16. Pregnant and lactating women; For women of childbearing age who have not undergone&#xD;
             sterilization surgery: do not agree to use appropriate methods of contraception;&#xD;
&#xD;
         17. For men not undergoing sterilization: do not agree to use the barrier method of&#xD;
             contraception;&#xD;
&#xD;
         18. Other circumstances considered inappropriate for the study by the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yuankai Shi, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yuankai Shi, PhD</last_name>
    <phone>010-67781331</phone>
    <email>syuankaipumc@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Bengbu Medical College</name>
      <address>
        <city>Bengbu</city>
        <state>Anhui</state>
        <zip>100000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yanli Yang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hui Liu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Shijitan hospital, capital medical university</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>xinghe wang</last_name>
    </contact>
    <contact_backup>
      <last_name>weijing Zhang</last_name>
    </contact_backup>
    <investigator>
      <last_name>weijing Zhang</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xinghe Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer hospital, Chinese academy of medical sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuankai Shi, PhD</last_name>
      <phone>010-67781331</phone>
      <email>syuankaipumc@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Hebei University</name>
      <address>
        <city>Baoding</city>
        <state>Hebei</state>
        <zip>100000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aimin Zhang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henan Tumor Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>100000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yufu Li</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hunan Cancer Hospital</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>100000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hui Zhou</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital of Soochow University</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <zip>100000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhengming, Jin</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>100000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sujun Gao</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tianjin People's Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>100000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huaqing Wang</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 5, 2020</study_first_submitted>
  <study_first_submitted_qc>March 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 11, 2020</study_first_posted>
  <last_update_submitted>August 2, 2021</last_update_submitted>
  <last_update_submitted_qc>August 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CD20+</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

